<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39369361</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1699-3055</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Clinical &amp; translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</Title><ISOAbbreviation>Clin Transl Oncol</ISOAbbreviation></Journal><ArticleTitle>Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12094-024-03744-6</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The COVID-19 pandemic is a great burden worldwide, but its impact on patients with genitourinary cancer (GUC) is poorly characterized. This study aimed to characterize the clinical features and evolution of GUC patients affected by COVID-19 in Spain.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">SOGUG-COVID-19 was an observational ambispective non-interventional study that recruited patients with SARS-CoV-2 infection who had been treated for GUC in 32 Spanish hospitals. Data were collected from patients' medical records in a short period of time, coinciding with the first waves of COVID-19, when the mortality was also higher in the general population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From November 2020 to April 2021, 408 patients were enrolled in the study. The median age was 70 years, and 357 patients (87.5%) were male. Most frequent Cancer Origin was: prostate (40.7%), urothelial (31.4%) and kidney (22.1%). Most patients (71.3%) were diagnosed at the metastatic stage, and 33.3% had poorly differentiated histology. Anticancer treatment during the infection was reported in 58.3% of patients, and 21.3% had received immunotherapy prior to or concurrent with the infection. The most frequent COVID-19 symptoms were pyrexia (49.0%), cough (38.2%) and dyspnea (31.9%). Median age was higher for patients with pneumonia (p &lt; 0.001), patchy infiltrates (p = 0.005), ICU admission (p &lt; 0.001) and death (p &lt; 0.001). Tumor stage was associated with complications (p = 0.006). The fatality rate was 19.9% and the 6-month COVID-19-specific survival rate was 79.7%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with genitourinary cancers seem exceptionally vulnerable to COVID-19 regardless of tumor type or anticancer therapy. Age and tumor stage were the only identified risk factors for severe COVID-19.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Climent</LastName><ForeName>Miguel Ángel</ForeName><Initials>MÁ</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Méndez-Vidal</LastName><ForeName>María José</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Medical Oncology Department, Córdoba, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anguera</LastName><ForeName>Georgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez Salas</LastName><ForeName>Imanol</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Fundación Jiménez Díaz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallardo</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuéllar-Rivas</LastName><ForeName>Miler Andrés</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Institut Català d'Oncologia (ICO) L'Hospitalet del Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina-Cerrillo</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martín</LastName><ForeName>Almudena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Vida</LastName><ForeName>Alejo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital del Mar, IMIM Research Institute, CIBERONC, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almagro Casado</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Quirón Salud Madrid, Pozuelo de Alarcón, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Macarena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domènech</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Fundación Althaia, Manresa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez Kareaga</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Txagorritxu, Vitoria Gasteiz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández Calvo</LastName><ForeName>Ovidio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa Guzmán</LastName><ForeName>José Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez Estévez</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Del-Alba</LastName><ForeName>Aránzazu</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6570-009X</Identifier><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, C/Joaquin Rodrigo 2, Majadahonda, 28222, Madrid, Spain. aranzazu.gonzalezalba@salud.madrid.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puente</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Transl Oncol</MedlineTA><NlmUniqueID>101247119</NlmUniqueID><ISSNLinking>1699-048X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Genitourinary cancer</Keyword><Keyword MajorTopicYN="N">Prognostic factors</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39369361</ArticleId><ArticleId IdType="doi">10.1007/s12094-024-03744-6</ArticleId><ArticleId IdType="pii">10.1007/s12094-024-03744-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30096-6</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId><ArticleId IdType="pmc">7159000</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17:519–27.</Citation><ArticleIdList><ArticleId IdType="doi">10.20892/j.issn.2095-3941.2020.0289</ArticleId><ArticleId IdType="pubmed">32944387</ArticleId><ArticleId IdType="pmc">7476081</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuzzi AF, Ciccarelli M, Marrari A, Gennaro N, Dipasquale A, Giordano L, et al. Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an academic hospital in Lombardy. Italy Br J Cancer. 2021;125:358–65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-021-01396-9</ArticleId><ArticleId IdType="pubmed">33976367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020;5:e444–51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(20)30146-8</ArticleId><ArticleId IdType="pubmed">32619408</ArticleId><ArticleId IdType="pmc">7326416</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized With COVID-19 in the New York City area. JAMA. 2020;323:2052–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.6775</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId><ArticleId IdType="pmc">7177629</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu Y-C, Sung Y-C, Ramjiawan RR, Lin T-T, Chang C-C, et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep. 2017;7:44123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44123</ArticleId><ArticleId IdType="pubmed">28276530</ArticleId><ArticleId IdType="pmc">5343435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId><ArticleId IdType="pmc">7270627</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu C-Y, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32:787–800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.02.024</ArticleId><ArticleId IdType="pubmed">33746047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA: J Am Med Assoc. 2020;323:1239–42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Han H, He T, Labbe KE, Hernandez AV, Chen H, et al. Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2021;113:371–80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djaa168</ArticleId><ArticleId IdType="pubmed">33136163</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan. China Ann Oncol. 2020;31:894–901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.03.296</ArticleId><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0422</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId><ArticleId IdType="pmc">7309152</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:904–13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30310-7</ArticleId><ArticleId IdType="pubmed">32479787</ArticleId><ArticleId IdType="pmc">7259917</ArticleId></ArticleIdList></Reference><Reference><Citation>Burki TK. Cancer care in the time of COVID-19. Lancet Oncol. 2020;21:628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30201-1</ArticleId><ArticleId IdType="pubmed">32213339</ArticleId><ArticleId IdType="pmc">7156149</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier J-B, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31173-9</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId><ArticleId IdType="pmc">7255715</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020;130:6656–67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141777</ArticleId><ArticleId IdType="pubmed">32897885</ArticleId><ArticleId IdType="pmc">7685738</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Yang D, Chen X, Sun Z, Zou Y, Chen C, et al. The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis. Cancer Med. 2021;10:1043–56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3692</ArticleId><ArticleId IdType="pubmed">33381923</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo-Bravo L, Sierra Moros MJ, Martínez Sánchez EV, Lorusso N, Carmona Ubago A, Gallardo García V, et al. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill. 2020;25:2001431.</Citation><ArticleIdList><ArticleId IdType="pmc">7812423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimafeyeu I, Volkova M, Alekseeva G, Berkut M, Nosov A, Myslevtsev I, et al. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies. J Hematol Oncol. 2021;14:192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01205-z</ArticleId><ArticleId IdType="pubmed">34774086</ArticleId><ArticleId IdType="pmc">8590125</ArticleId></ArticleIdList></Reference><Reference><Citation>Kläser K, Molteni E, Graham M, Canas LS, Österdahl MF, Antonelli M, et al. 2022 COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Sci Rep. 2022;12:10904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-14016-0</ArticleId><ArticleId IdType="pubmed">35764879</ArticleId><ArticleId IdType="pmc">9240087</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 2021;9:82–93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30405-8</ArticleId><ArticleId IdType="pubmed">33357491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31187-9</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId><ArticleId IdType="pmc">7255743</ArticleId></ArticleIdList></Reference><Reference><Citation>Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30314-4</ArticleId><ArticleId IdType="pubmed">32539942</ArticleId><ArticleId IdType="pmc">7292610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020;10:1465–74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0773</ArticleId><ArticleId IdType="pubmed">32737082</ArticleId><ArticleId IdType="pmc">7668225</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21:893–903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30309-0</ArticleId><ArticleId IdType="pubmed">32479790</ArticleId><ArticleId IdType="pmc">7259911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei H, Dong X, Wang Y, Tang L, Hu Y. Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan. Lancet Oncol. 2020;21:634–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30238-2</ArticleId><ArticleId IdType="pubmed">32359487</ArticleId><ArticleId IdType="pmc">7252194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuzzi AF, Marrari A, Gennaro N, Cariboni U, Ciccarelli M, Giordano L, et al. Low incidence of SARS-CoV-2 in patients with solid tumours on active treatment: an observational study at a tertiary cancer centre in lombardy, Italy. Cancers (Basel). 2020;12:2352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12092352</ArticleId><ArticleId IdType="pubmed">32825295</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, Fehrmann RSN, van Binnendijk RS, Dingemans AMC, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021;22:1681–91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00574-X</ArticleId><ArticleId IdType="pubmed">34767759</ArticleId><ArticleId IdType="pmc">8577843</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldhorn I, Holland R, Goshen-Lago T, Shirman Y, Szwarcwort-Cohen M, Reiner-Benaim A, et al. Six-month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. 2021;11:2430–5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1072</ArticleId><ArticleId IdType="pubmed">34475136</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>